Miami, FL. June 16, 2019 – It is with great excitement that we announce that Nordic Capital has entered into a definitive agreement to acquire ArisGlobal.
Six months ago, ArisGlobal set out on a mission to find a large investor to support its rapid growth. This was a carefully administered process that required close engagement with several top healthcare investors as we searched for the best partner for ArisGlobal. Today, we are pleased to announce that we have found the right one.
Nordic Capital was an obvious choice thanks to their deep experience in healthcare and technology, and a shared vision for the future of drug development software. A world-class firm with a global footprint, Nordic Capital has an extensive record of successful investments in life sciences, including their stewardship of firms like Nycomed, ERT and Acino.
“The last two years have seen significant growth for ArisGlobal. We feel that this growth has validated our approach to the industry and our LifeSphere® platform, and we have a clear vision for the future. To further execute this vision, our team determined that it made sense to partner with an investor that was experienced in scaling a technology company within the life sciences industry. The partnership with Nordic Capital will provide resources in the form of funding, personnel, relationships and industry expertise, that will allow us to take ArisGlobal to the next level. Given our success in recent years, we felt that the time was now to pursue this type of partnership,” added Sankesh Abbhi, ArisGlobal CEO.
ArisGlobal traces its roots back to 1987 when founder Deepak Abbhi pioneered the development of a first-in-industry adverse event management system that would help life sciences firms automate their mission critical global pharmacovigilance functions for patient safety and regulatory compliance. Over 32 years, ArisGlobal has built a sustainable and growing business that thrives on its partnerships with many life sciences companies and regulatory agencies. These customer relationships, some lasting decades, have positioned the company as a healthcare technology leader with over 1200 employees across an expansive global footprint.
Moving forward, ArisGlobal’s management team will remain dedicated to the company full-time and will continue to manage it as a standalone entity for the years ahead.
“The goal is to continue our strong growth through product innovation, customer satisfaction and industry thought leadership. We are confident that the resources and expertise provided by Nordic Capital will help us achieve this. We feel that all our customers will benefit from this partnership as well,” mentioned Sankesh Abbhi.
The ArisGlobal acquisition comes as Nordic Capital readies to expand its already big bet on the investment prospects of the U.S. health-care sector. Since its inception in 1989, the buyout firm has invested a total of €5.4 billion ($6.01 billion) in health-care companies, directing more than 25% of that total to the health-care sector in the U.S.
ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® is a unified platform that boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant SaaS architecture.